Skip to main content
Erschienen in: Cancer Causes & Control 2/2007

01.03.2007 | Original Paper

How valid is using cancer registries’ data to identify acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma?

verfasst von: Catherine Diamond, Thomas H. Taylor, Theresa Im, Mark Wallace, Alan Saven, Hoda Anton-Culver

Erschienen in: Cancer Causes & Control | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Objective

We sought to determine the accuracy of cancer registry data regarding the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) status of patients with non-Hodgkin’s lymphoma (NHL).

Methods

We used the population-based San Diego/Orange County cancer registry to identify 392 patients with HIV-related NHL diagnosed 1994–1999. After matching for age, sex, race, period of NHL diagnosis, and hospital type, we were able to find 324 corresponding patients among the remaining 4,863 NHL patients diagnosed 1994–1999 (who did not have HIV infection according to cancer registry records). We sought to review these patients’ charts at 41 hospitals with 15 separate institutional review boards to determine if the HIV serostatus from the cancer registry was correct. We performed a forward conditional multivariate logistic regression to determine characteristics associated with a false positive HIV status.

Results

The false positive rate was 8% while the false negative rate was 3%. The positive predictive value was 93% while the negative predictive value was 97%. Compared to correctly identified patients, false positives were more likely to be ≥50 years old, female, and treated with chemotherapy and less likely to be single with high grade or extranodal disease.

Conclusion

Using cancer registry data to identify AIDS-related NHL is a valid research practice.
Literatur
1.
Zurück zum Zitat Palella FJ Jr, Delaney KM, Moorman AC, et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853–860PubMedCrossRef Palella FJ Jr, Delaney KM, Moorman AC, et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853–860PubMedCrossRef
2.
Zurück zum Zitat State of California Department of Health Standards, Cancer Surveillance Section. California Cancer Registry Data Standards, Assessment Unit. Cancer Reporting in California: Abstracting and Coding Procedures for Hospitals. Volume One Fifth Edition May 1998 State of California Department of Health Standards, Cancer Surveillance Section. California Cancer Registry Data Standards, Assessment Unit. Cancer Reporting in California: Abstracting and Coding Procedures for Hospitals. Volume One Fifth Edition May 1998
3.
Zurück zum Zitat Seiffert JE, Price WT, Gordon B (1990) The California tumor registry: a state-of-the-art model for a regionalized, automated, population-based registry. Top Health Rec Manage 11:59–73PubMed Seiffert JE, Price WT, Gordon B (1990) The California tumor registry: a state-of-the-art model for a regionalized, automated, population-based registry. Top Health Rec Manage 11:59–73PubMed
4.
Zurück zum Zitat Diamond C, Taylor TH, Im T, Anton-Culver H (2006) Presentation and outcomes of systemic non-Hodgkin’s lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma 47:1822–1829PubMedCrossRef Diamond C, Taylor TH, Im T, Anton-Culver H (2006) Presentation and outcomes of systemic non-Hodgkin’s lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma 47:1822–1829PubMedCrossRef
6.
Zurück zum Zitat Percy C, Van Holten V, Muir C (eds) (1990) International Classification of Diseases for Oncology. England: World Health Organization, pp. xxxii–xxxvi Percy C, Van Holten V, Muir C (eds) (1990) International Classification of Diseases for Oncology. England: World Health Organization, pp. xxxii–xxxvi
7.
Zurück zum Zitat Fritz A, Ries L (eds) (1998) SEER Extent of Disease-1988 Codes and Coding Instructions. Bethesda, Maryland: Cancer Statistics Branch, National Institutes of Health, P. 180 Fritz A, Ries L (eds) (1998) SEER Extent of Disease-1988 Codes and Coding Instructions. Bethesda, Maryland: Cancer Statistics Branch, National Institutes of Health, P. 180
9.
Zurück zum Zitat American Hospital Association (2001) AHA Guide to the Health Care Field. Chicago, IL: Health Forum LLC American Hospital Association (2001) AHA Guide to the Health Care Field. Chicago, IL: Health Forum LLC
10.
Zurück zum Zitat Zar JH (1984) Biostatistical Analysis. Englewood Cliffs, NJ: Prentice Hall, p. 378 Zar JH (1984) Biostatistical Analysis. Englewood Cliffs, NJ: Prentice Hall, p. 378
11.
Zurück zum Zitat Diamond C, Taylor TH, Aboumrad T, Anton-Culver H (2006) Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 106:128–135PubMedCrossRef Diamond C, Taylor TH, Aboumrad T, Anton-Culver H (2006) Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 106:128–135PubMedCrossRef
12.
Zurück zum Zitat Mocroft A, Katlama C, Johnson AM, et al (2000) AIDS across Europe, 1994–1998, the EuroSIDA Study. Lancet 356:291–296PubMedCrossRef Mocroft A, Katlama C, Johnson AM, et al (2000) AIDS across Europe, 1994–1998, the EuroSIDA Study. Lancet 356:291–296PubMedCrossRef
13.
Zurück zum Zitat Cote TR, O’Brien TR, Ward JW, Wilson SE, Blattner WA, National AIDS/Cancer Match Study Group (1995) AIDS and cancer registry linkage: measurement and enhancement of registry completeness. Prev Med 24:375–377PubMedCrossRef Cote TR, O’Brien TR, Ward JW, Wilson SE, Blattner WA, National AIDS/Cancer Match Study Group (1995) AIDS and cancer registry linkage: measurement and enhancement of registry completeness. Prev Med 24:375–377PubMedCrossRef
14.
Zurück zum Zitat Cote TR, Biggar RJ, Rosenberg PS, et al (1997) Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation, and public health burden. Int J Cancer 73:645–650PubMedCrossRef Cote TR, Biggar RJ, Rosenberg PS, et al (1997) Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation, and public health burden. Int J Cancer 73:645–650PubMedCrossRef
15.
Zurück zum Zitat Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG (2000) Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 96:2730–2734PubMed Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG (2000) Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 96:2730–2734PubMed
16.
Zurück zum Zitat Hooper WC, Holman RC, Clarke MJ, Chorba TL (2001) Trends in non-Hodgkin lymphoma (NHL) and HIV-associated NHL deaths in the United States. Am J Hematol 66:159–166PubMedCrossRef Hooper WC, Holman RC, Clarke MJ, Chorba TL (2001) Trends in non-Hodgkin lymphoma (NHL) and HIV-associated NHL deaths in the United States. Am J Hematol 66:159–166PubMedCrossRef
17.
Zurück zum Zitat Clarke CA, Glaser SL (2004) Population-based surveillance of HIV-associated cancers: utility of cancer registry data. J Acquir Immune Defic Syndr 36:1083–1091PubMed Clarke CA, Glaser SL (2004) Population-based surveillance of HIV-associated cancers: utility of cancer registry data. J Acquir Immune Defic Syndr 36:1083–1091PubMed
18.
Zurück zum Zitat Department of Veteran’s Affairs. Privacy and Release of Information, VHA handbook 1605.1. Washington DC, 2002 Department of Veteran’s Affairs. Privacy and Release of Information, VHA handbook 1605.1. Washington DC, 2002
19.
Zurück zum Zitat Anton-Culver H, Trejo R, Taylor TH, et al (2003) Cancer Incidence and Mortality in Orange County, 1996–2000. Irvine: Cancer Surveillance Program of Orange County/San Diego Imperial Organization for Cancer Control, Epidemiology Division, Department of Medicine, University of California, Irvine Anton-Culver H, Trejo R, Taylor TH, et al (2003) Cancer Incidence and Mortality in Orange County, 1996–2000. Irvine: Cancer Surveillance Program of Orange County/San Diego Imperial Organization for Cancer Control, Epidemiology Division, Department of Medicine, University of California, Irvine
20.
Zurück zum Zitat Anton-Culver H, Trejo R, Taylor TH, et al (2003) Cancer Incidence and Mortality in San Diego County, 1996–2000. Irvine: Cancer Surveillance Program of Orange County/San Diego Imperial Organization for Cancer Control, Epidemiology Division, Department of Medicine. University of California, Irvine Anton-Culver H, Trejo R, Taylor TH, et al (2003) Cancer Incidence and Mortality in San Diego County, 1996–2000. Irvine: Cancer Surveillance Program of Orange County/San Diego Imperial Organization for Cancer Control, Epidemiology Division, Department of Medicine. University of California, Irvine
21.
Zurück zum Zitat Christian MC, Goldberg JL, Killen J, et al (2002) A central institutional review board for multi-institutional trials. N Engl J Med 346:1405–1408PubMedCrossRef Christian MC, Goldberg JL, Killen J, et al (2002) A central institutional review board for multi-institutional trials. N Engl J Med 346:1405–1408PubMedCrossRef
22.
Zurück zum Zitat Humphreys K, Trafton J, Wagner TH (2003) The cost of institutional review board procedures in multicenter observational research. Ann Intern Med 139:77PubMed Humphreys K, Trafton J, Wagner TH (2003) The cost of institutional review board procedures in multicenter observational research. Ann Intern Med 139:77PubMed
23.
Zurück zum Zitat Annas GJ (2002) Medical privacy and medical research–judging the new federal regulations. N Engl J Med 346:216–220PubMedCrossRef Annas GJ (2002) Medical privacy and medical research–judging the new federal regulations. N Engl J Med 346:216–220PubMedCrossRef
24.
Zurück zum Zitat Kulynych J, Korn D (2002) The effect of the new federal medical-privacy rule on research. N Engl J Med 346:201–204PubMedCrossRef Kulynych J, Korn D (2002) The effect of the new federal medical-privacy rule on research. N Engl J Med 346:201–204PubMedCrossRef
25.
Zurück zum Zitat Ingelfinger JR, Drazen JM (2004) Registry research and medical privacy. N Engl J Med 350:1452–1453PubMedCrossRef Ingelfinger JR, Drazen JM (2004) Registry research and medical privacy. N Engl J Med 350:1452–1453PubMedCrossRef
26.
Zurück zum Zitat Holly EA, Gautam M, Bracci PM (2002) Comparison of interviewed and non-interviewed non-Hodgkin’s lymphoma (NHL) patients in the San Francisco Bay Area. Ann Epidemiol 12:419–425PubMedCrossRef Holly EA, Gautam M, Bracci PM (2002) Comparison of interviewed and non-interviewed non-Hodgkin’s lymphoma (NHL) patients in the San Francisco Bay Area. Ann Epidemiol 12:419–425PubMedCrossRef
Metadaten
Titel
How valid is using cancer registries’ data to identify acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma?
verfasst von
Catherine Diamond
Thomas H. Taylor
Theresa Im
Mark Wallace
Alan Saven
Hoda Anton-Culver
Publikationsdatum
01.03.2007
Verlag
Kluwer Academic Publishers
Erschienen in
Cancer Causes & Control / Ausgabe 2/2007
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-006-0096-5

Weitere Artikel der Ausgabe 2/2007

Cancer Causes & Control 2/2007 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.